AI-generated analysis. Always verify with the original filing.
Lyell Immunopharma, Inc. appointed Smital Shah as Chief Financial and Business Officer and principal financial officer effective March 9, 2026, succeeding Lynn Seely, M.D., who previously served as interim principal financial officer. The appointment includes an annual base salary of $500,000, target bonus up to 50% of base salary, and a stock option for 140,000 shares.
Event Type
Disclosure
Mandatory
Variant
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On March 6,
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Offer Letter, dated March 3, 2026, by and between Smital Shah and Lyell Immunoph
Smital Shah
Effective: 2026-03-09
Lynn Seely, M.D.
Effective: 2026-03-09
Appointment of Smital Shah